Cambridge Neurotherapeutics is a preclinical-stage biotechnology company focused on translating neuroscience research into disease-modifying treatments for people living with ALS and their families.
Meet the Team
ALS is a rapidly progressing neurodegenerative disease with no cure and few effective treatment options. We are building a pipeline of therapeutic candidates aimed at the underlying mechanisms of motor neuron degeneration, with the goal of extending survival and quality of life for patients.
Our research program is grounded in the latest understanding of ALS disease biology and motor neuron degeneration.
Every program decision is made with the urgency of the ALS patient community in mind.
We hold our preclinical and translational work to the highest scientific and regulatory standards.
We are advancing a novel therapeutic candidate designed to target key drivers of motor neuron loss in ALS. Our current work spans target validation, lead optimization, and preclinical characterization as we prepare for future development milestones.
Ongoing studies to characterize mechanism of action, efficacy, and safety in relevant disease models.
A development plan informed by the ALS clinical and regulatory landscape, built to move efficiently toward the clinic.
For inquiries about our research, partnerships, or funding opportunities, please reach out.
Email: info@cambridgeneuro.com